omeprazole has been researched along with erlotinib hydrochloride in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Bradbury, PA; Hilton, JF; Seymour, L; Shepherd, FA; Tu, D | 1 |
Basappa, N; Butts, CA; Chambers, CR; Chu, MP; Chu, Q; Fenton, D; Ghosh, S; Joy, AA; Sangha, R; Sawyer, MB; Smylie, M | 1 |
Lin, C; Lin, G; Ma, J; Wang, S; Wang, X; Zhang, M; Zhang, Q; Zhou, Y | 1 |
Abt, M; Ducray, PS; Giraudon, M; Hamilton, M; Kletzl, H; Lum, BL | 1 |
Nagase, K; Ogawa, Y; Okano, M; Sai, Y; Shimada, T; Ueda, A; Yamada, M | 1 |
1 trial(s) available for omeprazole and erlotinib hydrochloride
Article | Year |
---|---|
Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Gastric Acid; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quinazolines; Ranitidine; Young Adult | 2015 |
4 other study(ies) available for omeprazole and erlotinib hydrochloride
Article | Year |
---|---|
An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib.
Topics: Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Ranitidine; Retrospective Studies; Stomach Ulcer; Treatment Outcome | 2013 |
Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Female; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Omeprazole; Population Groups; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Simultaneous determination of bupropion, metroprolol, midazolam, phenacetin, omeprazole and tolbutamide in rat plasma by UPLC-MS/MS and its application to cytochrome P450 activity study in rats.
Topics: Adjuvants, Anesthesia; Analgesics, Non-Narcotic; Animals; Antidepressive Agents, Second-Generation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Erlotinib Hydrochloride; Hypoglycemic Agents; Limit of Detection; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Phenacetin; Protein Kinase Inhibitors; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Tolbutamide | 2015 |
Administration of erlotinib in apple juice overcomes decreased absorption in a rat model of gastric acid suppression.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Erlotinib Hydrochloride; Food-Drug Interactions; Fruit and Vegetable Juices; Gastric Acid; Gastric Mucosa; Gastrointestinal Absorption; Hydrogen-Ion Concentration; Male; Malus; Omeprazole; Proton Pump Inhibitors; Rats, Wistar; Solubility | 2020 |